KD Pharma Group

Name

KD Pharma Group

Legal name

KD Pharma Group SA

Website

https://kdpharmagroup.com

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

Keywords

• Omega-3 manufacturing
• Pharmaceutical CDMO services
• Lipid extraction technology
• Nutraceutical contract manufacturing
• Supercritical fluid chromatography

Headquarters

HQ city

Bioggio

HQ country

Switzerland

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Organization (CDMO) Services: KD Pharma Group operates as a pure-play technology-driven CDMO providing vertically integrated manufacturing services across lipids and small molecules. Revenue is generated through custom synthesis, API manufacturing, and finished dosage form services for pharmaceutical and nutraceutical customers. Services span from R&D development through pilot plant cGMP for clinical supplies to large-scale commercial cGMP production.
2. Omega-3 API and Ingredient Sales: Sale of pharmaceutical-grade Omega-3 APIs and concentrated ingredients to pharmaceutical and nutraceutical companies. The company supplies bulk API oil as well as bulk softgel capsules to major Omega-3 pharmaceutical markets including USA, EU, Korea and Japan.
3. Finished Dosage Form Manufacturing: Manufacturing and sale of finished products including softgels, liquid solutions, and packaging services for nutritional market customers. Turnkey solutions from ingredient through finished packaged product.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

KD Pharma Group is a pure-play, technology-driven Contract Development and Manufacturing Organization (CDMO) that delivers vertically integrated services and products for pharmaceutical and nutraceutical customers, spanning lipid-based APIs and ingredients (especially omega-3 fish and algae oils up to 99% purity), custom synthesis of small molecule intermediates and APIs, finished dosage form manufacturing (softgels, liquids, emulsions, bottling and packaging), and independent lipid analytical laboratory services through KD LabService.

Product overview

KD Pharma Group is a technology-driven Contract Development and Manufacturing Organization (CDMO) offering vertically integrated pharmaceutical and nutraceutical solutions. The company operates across three core technology platforms: kd-pür® extraction and purification technologies (including Supercritical Fluid Extraction, Supercritical Fluid Chromatography, Enhanced Silver Technology, and Simulated Moving Bed chromatography), synthesis technologies (high pressure reactions, cryogenic chemistry, chiral separations), and Innovagel® softgel technologies. Product portfolio includes Omega-3 APIs and concentrates up to 99% purity (fish and algae-based via Alga3™ brand), custom synthesis of pharmaceutical intermediates and APIs, finished dosage forms (softgels, liquids, emulsions), KD LabService™ independent lipid analysis laboratory, KD Phyto™ cannabinoid products, and branded formulations like Move3® joint health and ReGen3™ omega-3. Recent acquisition of dsm-firmenich's MEG-3® fish oil business expanded manufacturing footprint and product range. KD Pharma serves pharmaceutical, nutritional supplement, and specialty chemical markets with facilities in Germany, Norway, UK, Canada, Peru, USA, and Switzerland.

Differentiator

Problem solved

Functional benefit

Brands

• OceanBlue: Nutritional consumer brand owned by KD Pharma Group providing data on consumer perceptions of KD Nutra Omega-3 solutions.
• MEG-3
• Alga3
• kd-pur
• Innovagel
• ReGen3
• Kardio3
• Move3
• EPAspire

Products and services

• Custom Synthesis Services Full spectrum drug substance CDMO services from R&D development through pilot plant cGMP for clinical supplies to large-scale commercial cGMP production of APIs, intermediates, and specialty chemicals. Includes high pressure reactions (H2, CO2, CO, NH3), cryogenic chemistry down to -90°C, and chiral separations via SMB chromatography. Targets pharmaceutical companies needing complex multi-step synthesis.
• Omega-3 APIs and Concentrates Pharmaceutical and nutraceutical-grade omega-3 APIs and concentrates in fish oil and algae-based varieties, available in purity levels up to 99% from cGMP manufacturing facilities. Supplied as bulk API oil and bulk softgel capsules to major Omega-3 pharmaceutical markets including USA, EU, Korea and Japan.
• Finished Dosage Forms Turnkey softgel, liquid, and emulsion manufacturing services including formulation development, encapsulation processing (size 2 oval to size 28 oblong), bottling, and packaging for nutritional and pharmaceutical products. Backed by the Miami softgel center of excellence with capacity of 2 billion softgels per year across 7 encapsulation production lines.
• KD LabService Independent contract lipid analysis laboratory providing highly accurate testing services for omega-3 oils under cGMP conditions, offering titration, GC, HPLC, UV/FTIR, and physical analysis methods. ISO 17025:2018 certified. Recipient of GOED Special Achievement Program recognition in 2024 and 2025-2026.
• KD Phyto Cannabinoid APIs Cannabinoid business unit manufacturing pharmaceutical-grade CBD and other cannabinoid Active Pharmaceutical Ingredients (APIs) using proprietary lipid extraction and purification technologies. Includes 51% stake in Trigal Pharma which distributes CBD API through magistral preparations channel in Austria and Germany.
• Alga3 Vegan Omega-3 Platform Sustainable vegan omega-3 platform delivering microalgae-derived oils with customizable EPA:DHA ratios up to 95% concentration, providing plant-based alternatives to fish oil products. V-Label Vegan certified at Bexbach, Germany.
• Move3 Joint Health Formula Joint health formula combining kd-pur omega-3 fish oil with NEM (Natural Eggshell Membrane) eggshell membrane, clinically proven to reduce joint pain, stiffness and cartilage degradation in healthy adults. Developed in global exclusive partnership with Stratum Nutrition.
• EPAspire Drug Candidate Novel oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules, in Phase 3 clinical trials for Familial Adenomatous Polyposis (FAP), Ulcerative Colitis, and COVID-19 treatment. Developed in partnership with SLA Pharma. MHRA approved trial with FDA application submitted.
• ReGen3 Next-Generation Omega-3 Next-generation omega-3 concentrate with enriched pre-resolving mediators (PRMs) offering enhanced anti-inflammatory and resolution benefits compared to standard EPA and DHA products.
• MEG-3 Fish Oil Omega-3 Brand Premium fish oil omega-3 brand acquired from dsm-firmenich as part of the Marine Lipids business, covering food, beverage, dietary supplement and pharmaceutical applications globally.

Quantifiable outcome

• 60-75% reduction in CO2 emissions at German production sites
• +2 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• dsm-firmenichcoreStrategic or Co-development Partner · 31 December 2025KD Swiss GmbH signed agreement to acquire the distribution and supply of the food-grade oil business from dsm-firmenich. Acquisition financed by shareholder loan. Closing expected without conditions precedent.
• dsm-firmenichcoreStrategic or Co-development Partner · 1 October 2024KD Pharma Group completed acquisition of dsm-firmenich's Marine Lipids business including MEG-3® brand and production facilities in Peru and Canada. In return, dsm-firmenich received a minority stake in the enlarged KD group. This transaction positions KD Pharma as the largest omega-3 manufacturer in the world.
• GOED (Global Organization for EPA and DHA Omega-3s)minorOthers · 23 July 2024KD LabService received GOED Special Achievement Program recognition for excellence in AOCS Laboratory Proficiency Program for omega-3 analysis. GOED promotes omega-3 education and standards across the industry.
• Trigal PharmacoreStrategic or Co-development Partner · 4 October 2021KD Pharma Group acquired 51% stake in Trigal Pharma, a company specialized in clinical research, development and marketing of medical cannabinoids including Cannabidiol (CBD) in highly-purified form. Trigal manufactures and distributes CBD API through magistral preparations channel in Austria and Germany.
• Stratum NutritioncoreStrategic or Co-development Partner · 5 August 2020Global exclusive partnership to develop MOVE3® combining Stratum's NEM® brand eggshell membrane and KD Pharma's kd-pür® marine omega oils. Product marketed in softgels via both companies' global sales forces. Published clinical study showing significant reductions in joint pain and stiffness.
• SLA PharmacoreStrategic or Co-development Partner · 14 April 2020Partnership for development of EPAspire™ drug candidate entering clinical trials for COVID-19 treatment. SLA Pharma leads clinical development while KD Pharma provides highly purified EPA-FFA formulation. MHRA approved trial with discussions ongoing in other European countries and FDA application submitted.

Scale indicators8 records

Recent moves10 records

Expansion highlights6 records

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/kd-pharma/?viewAsMember=true
• Xx.com/KDPharmaGroup

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries11 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KD Pharma Group